CD8A and neoplasm: The inhibition of cholesterol esterification by the enzyme cholesterol acyltransferase 1 (ACAT1) utilising the repurposed drug avasimibe leads to an improved anti-tumour response by CD8+ T cells that further enhanced outcomes in combination therapy with anti-PD-1 treatment [61].